These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 9322850)
1. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. Antinheimo J; Haapasalo H; Haltia M; Tatagiba M; Thomas S; Brandis A; Sainio M; Carpen O; Samii M; Jääskeläinen J J Neurosurg; 1997 Oct; 87(4):610-4. PubMed ID: 9322850 [TBL] [Abstract][Full Text] [Related]
2. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry. Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919 [TBL] [Abstract][Full Text] [Related]
4. A role for the p53 pathway in the pathology of meningiomas with NF2 loss. Chang Z; Guo CL; Ahronowitz I; Stemmer-Rachamimov AO; MacCollin M; Nunes FP J Neurooncol; 2009 Feb; 91(3):265-70. PubMed ID: 18974932 [TBL] [Abstract][Full Text] [Related]
5. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Abramovich CM; Prayson RA Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827 [TBL] [Abstract][Full Text] [Related]
6. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy. Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837 [TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas. Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878 [TBL] [Abstract][Full Text] [Related]
9. NF2 mutations in secretory and other rare variants of meningiomas. Hartmann C; Sieberns J; Gehlhaar C; Simon M; Paulus W; von Deimling A Brain Pathol; 2006 Jan; 16(1):15-9. PubMed ID: 16612978 [TBL] [Abstract][Full Text] [Related]
10. Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients. Nowak A; Dziedzic T; Czernicki T; Kunert P; Marchel A Neurol Neurochir Pol; 2015; 49(6):367-72. PubMed ID: 26652870 [TBL] [Abstract][Full Text] [Related]
11. Radiation-associated meningiomas in children: clinical, pathological, and cytogenetic characteristics with a critical review of the literature. Elbabaa SK; Gokden M; Crawford JR; Kesari S; Saad AG J Neurosurg Pediatr; 2012 Oct; 10(4):281-90. PubMed ID: 22900483 [TBL] [Abstract][Full Text] [Related]
12. NF2 status of meningiomas is associated with tumour localization and histology. Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370 [TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis. Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. Hansson CM; Buckley PG; Grigelioniene G; Piotrowski A; Hellström AR; Mantripragada K; Jarbo C; Mathiesen T; Dumanski JP BMC Genomics; 2007 Jan; 8():16. PubMed ID: 17222329 [TBL] [Abstract][Full Text] [Related]
15. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients. Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M J Neurosurg; 2021 May; 134(5):1377-1385. PubMed ID: 32442973 [TBL] [Abstract][Full Text] [Related]
16. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Saito K; Kato M; Susaki N; Nagatani T; Nagasaka T; Yoshida J Clin Neuropathol; 2003; 22(1):30-4. PubMed ID: 12617191 [TBL] [Abstract][Full Text] [Related]
17. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Abramovich CM; Prayson RA Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826 [TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397 [TBL] [Abstract][Full Text] [Related]
19. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Ho DM; Hsu CY; Ting LT; Chiang H Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512 [TBL] [Abstract][Full Text] [Related]
20. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Buccoliero AM; Castiglione F; R Degl'Innocenti D; Gheri CF; Garbini F; Taddei A; Ammannati F; Mennonna P; Taddei GL Neuropathology; 2007 Feb; 27(1):36-42. PubMed ID: 17319281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]